Latest news with #AbbVieInc
Yahoo
a day ago
- Business
- Yahoo
AbbVie Inc. (ABBV)'s Pipeline Advances with Temab-A and ABBV-706, Shares Flat
AbbVie Inc. (NYSE:ABBV) has spotlighted major advancements in its oncology pipeline at the ASCO 2025 Annual Meeting, unveiling promising clinical data for its next-generation antibody-drug conjugates (ADCs), Temab-A and ABBV-706. Temab-A, a c-Met-targeting ADC, achieved a 63% objective response rate in pre-treated EGFR-mutated non-small cell lung cancer (NSCLC) patients, with over half maintaining their response for at least six months, demonstrating efficacy across c-Met expression levels and supporting further clinical exploration. A doctor utilizing a cloud-based healthcare platform to access patient records. ABBV-706, which targets SEZ6, delivered a 61% confirmed response rate in second-line or later small cell lung cancer (SCLC), outperforming existing therapies in cross-trial comparisons, while also showing activity in high-grade neuroendocrine neoplasms. Both therapies utilize AbbVie Inc. (NYSE:ABBV)'s proprietary Top1i payload to induce targeted cancer cell death, reinforcing the company's commitment to addressing difficult-to-treat tumors. Despite these clinical milestones, AbbVie Inc. (NYSE:ABBV)'s stock price remained steady at around $187.15, mirroring broader market stability as investors await key financial updates. With a consensus price target of $210.68, analysts see an 11% upside, highlighting ABBV's robust long-term performance and future revenue potential as its innovative pipeline matures. While we acknowledge the potential of ABBV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABBV and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Sign in to access your portfolio
Yahoo
3 days ago
- Business
- Yahoo
AbbVie Inc. (ABBV)'s Pipeline Advances with Temab-A and ABBV-706, Shares Flat
AbbVie Inc. (NYSE:ABBV) has spotlighted major advancements in its oncology pipeline at the ASCO 2025 Annual Meeting, unveiling promising clinical data for its next-generation antibody-drug conjugates (ADCs), Temab-A and ABBV-706. Temab-A, a c-Met-targeting ADC, achieved a 63% objective response rate in pre-treated EGFR-mutated non-small cell lung cancer (NSCLC) patients, with over half maintaining their response for at least six months, demonstrating efficacy across c-Met expression levels and supporting further clinical exploration. A doctor utilizing a cloud-based healthcare platform to access patient records. ABBV-706, which targets SEZ6, delivered a 61% confirmed response rate in second-line or later small cell lung cancer (SCLC), outperforming existing therapies in cross-trial comparisons, while also showing activity in high-grade neuroendocrine neoplasms. Both therapies utilize AbbVie Inc. (NYSE:ABBV)'s proprietary Top1i payload to induce targeted cancer cell death, reinforcing the company's commitment to addressing difficult-to-treat tumors. Despite these clinical milestones, AbbVie Inc. (NYSE:ABBV)'s stock price remained steady at around $187.15, mirroring broader market stability as investors await key financial updates. With a consensus price target of $210.68, analysts see an 11% upside, highlighting ABBV's robust long-term performance and future revenue potential as its innovative pipeline matures. While we acknowledge the potential of ABBV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABBV and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None.
Yahoo
23-05-2025
- Business
- Yahoo
Key Drivers Behind AbbVie's (ABBV) Performance
RS Investments, an investment management company, released its 'RS Large Cap Value Strategy' first quarter 2025 investor letter. A copy of the letter can be downloaded here. In the first quarter, the strategy underperformed its benchmark, the Russell 1000 Value Index (the 'Index'), and returned 1.57% (net) versus a return of 2.14% for the Index. The strong performance from stock selection in Consumer Discretionary and Utilities aided relative performance in the quarter, while stock selection in Materials and Information Technology detracted. In addition, you can check the fund's top 5 holdings to determine its best picks for 2025. In its first-quarter 2025 investor letter, RS Large Cap Value Strategy highlighted stocks such as AbbVie Inc. (NYSE:ABBV). AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company. The one-month return of AbbVie Inc. (NYSE:ABBV) was 1.20%, and its shares gained 15.34% of their value over the last 52 weeks. On May 22, 2025, AbbVie Inc. (NYSE:ABBV) stock closed at $182.54 per share with a market capitalization of $322.439 billion. RS Large Cap Value Strategy stated the following regarding AbbVie Inc. (NYSE:ABBV) in its Q1 2025 investor letter: "AbbVie Inc. (NYSE:ABBV) was a strong positive contributor to performance during the first quarter of 2025. The stock benefited from a confluence of company-specific and macro drivers, including robust fourth-quarter results reported in February and renewed investor interest in the pharmaceutical sector broadly. AbbVie's fourth quarter earnings exceeded expectations on both revenue and EPS, driven by continued growth in its immunology and neuroscience franchises, alongside stabilizing trends in Humira sales post loss of patent exclusivity. Importantly, during the first quarter AbbVie announced a large licensing deal with Gubra (a Danish biotech company) which gives AbbVie co-development and co commercialization rights on their lead clinical-stage obesity drug. While still early in development, the asset provides optionality in one of the most attractive therapeutic areas in biopharma today and underscores management's willingness to reposition the company for long-term growth beyond its core inflammation franchise. On the macro front, pharmaceutical stocks in general rebounded after several years of relative underperformance as investors sought exposure to defensive, high-margin business models trading at modest valuations relative to the broader market. We remain constructive on AbbVie and believe the company is well-positioned to deliver high-single-digit earnings growth through the end of the decade, supported by durable franchises, a promising pipeline, and a healthy balance sheet." A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. AbbVie Inc. (NYSE:ABBV) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 85 hedge fund portfolios held AbbVie Inc. (NYSE:ABBV) at the end of the fourth quarter, compared to 68 in the third quarter. While we acknowledge the potential of AbbVie Inc. (NYSE:ABBV) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered AbbVie Inc. (NYSE:ABBV) and shared Renaissance Large Cap Growth Strategy's views on the company. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23-05-2025
- Business
- Yahoo
AbbVie Inc. (ABBV) Scores Major Legal Victory as Illinois Court Shuts Down $63 Billion Allergan Shareholder Lawsuit
AbbVie Inc. (NYSE:ABBV) has achieved a significant legal victory as the Illinois Appellate Court upheld the dismissal of a shareholder class action lawsuit stemming from its $63 billion acquisition of Allergan plc in 2020. The lawsuit, led by plaintiff Stephen Twigg on behalf of former U.S.-based Allergan shareholders, accused ABBV of improperly issuing unregistered shares during the merger. However, the appellate panel ruled that the share issuance was properly exempt under Section 3(a)(10) of the Securities Act of 1933, citing the fairness hearing held before Ireland's High Court as meeting all statutory requirements. The court emphasized that U.S. shareholders had the right to participate, including virtually, despite pandemic travel restrictions. The panel also rejected claims that AbbVie Inc. (NYSE:ABBV) failed to disclose objections from two dissenting FTC commissioners, noting those comments were public and had no bearing on the fairness of the transaction. Crucially, the court found Twigg had suffered no actual injury, as the AbbVie Inc. (NYSE:ABBV) shares he received increased in value by about $30 per share, making any reversal financially detrimental. This decision closes a major chapter of merger-related litigation and sets a precedent for future securities claims involving international fairness hearings. While we acknowledge the potential of ABBV to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than ABBV and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-05-2025
- Business
- Yahoo
AbbVie (ABBV) has a Stable and Highly Profitable Business Model
Renaissance Investment Management, an investment management company, released its Q1 2025 'Large Cap Growth Strategy' investor letter. A copy of the letter can be downloaded here. The S&P 500 experienced a 4.3% loss in Q1 due to uncertainty in technology stock valuations and US economic policies. However, seven sectors showed positive returns, with Energy, Health Care, and Utilities sectors showing the strongest performance. The S&P 500 has not experienced a significant correction since 2023, which can be expected to occur every couple of years. However, there are still good investment opportunities in high-quality, reasonably priced stocks that have not matched concentrated market indices. The S&P 500 (-4.3%) and Russell 1000 Growth Index (-10%) declined in Q1, with large-cap stocks outperforming smaller-cap stocks and Value outperforming Growth. For the quarter, the strategy exceeded the Russell 1000 Growth benchmark and lagged the S&P 500. For more information on the fund's best picks in 2025, please check its top five holdings. In its first-quarter 2025 investor letter, Renaissance Large Cap Growth Strategy highlighted stocks such as AbbVie Inc. (NYSE:ABBV). AbbVie Inc. (NYSE:ABBV) is a research-based biopharmaceutical company. The one-month return of AbbVie Inc. (NYSE:ABBV) was 0.79%, and its shares gained 14.87% of their value over the last 52 weeks. On May 21, 2025, AbbVie Inc. (NYSE:ABBV) stock closed at $181.80 per share with a market capitalization of $321.132 billion. Renaissance Large Cap Growth Strategy stated the following regarding AbbVie Inc. (NYSE:ABBV) in its Q1 2025 investor letter: "We also added a new position in the Health Care sector with AbbVie Inc. (NYSE:ABBV), a large biopharmaceutical company focused on immunology, virology, and oncology. We are attracted to AbbVie's stable and highly profitable business model which generates a high free cash-flow yield. AbbVie is coming off recent subdued growth following the patent expiration of Humira, its largest drug. We expect growth from its pharmaceutical portfolio to begin reaccelerating this year, with a solid drug pipeline that can be additive to future growth." A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. AAbbVie Inc. (NYSE:ABBV) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 85 hedge fund portfolios held AbbVie Inc. (NYSE:ABBV) at the end of the fourth quarter, compared to 68 in the third quarter. While we acknowledge the potential of AbbVie Inc. (NYSE:ABBV) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the undervalued AI stock set for massive gains. In another article, we covered AbbVie Inc. (NYSE:ABBV) and shared Carillon Eagle Growth & Income Fund's views on the company. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
